Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).
| Published in: | Cancer Chemotherapy & Pharmacology Vol. 95; no. 1; pp. 1 - 12 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Published: |
Springer Nature
2/28/2025
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=183375773&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 183375773 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 03445704 NO9 jtl: Cancer Chemotherapy & Pharmacology issn: 03445704 maglogo: N pubinfo: dt: 2/28/2025 vid: 95 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 183375773 10.1007/s00280-025-04753-0 183375773 ppf: 1 ppct: 11 formats: tig: atl: Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL). aug: au: Ouerdani, Aziz Valenzuela, Belén Treijtel, Nicoline Haddish-Berhane, Nahor Desphande, Sanjay Srinivasan, Srimathi Smith, Emma Perez Ruixo, Juan José affil: https://ror.org/04yzcpd71 Department of Clinical Pharmacology & Pharmacometrics, Johnson & Johnson, Beerse, Belgium sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|